- Home
- NEWP vs FTH Comparison
NEWP vs FTH Comparison
Compare NEWP & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$32.34
Company Overview
Basic Information| Metric | NEWP | FTH |
|---|---|---|
| Founded | 1972 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.6M | 860.0M |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEWP | FTH |
|---|---|---|
| Price | $6.84 | $32.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 570.1K | 280.1K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.55 | $17.50 |
| 52 Week High | $6.73 | $37.90 |
Technical Indicators
Market Signals| Indicator | NEWP | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 79.64 | 62.96 |
| Support Level | $3.44 | $22.69 |
| Resistance Level | N/A | $37.90 |
| Average True Range (ATR) | 0.34 | 3.01 |
| MACD | 0.19 | 0.31 |
| Stochastic Oscillator | 92.06 | 93.08 |
Price Performance
Historical Comparison NEWP
FTH
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.